Argent Biopharma (AU:RGT) has released an update.
Argent BioPharma Limited, a specialized biopharmaceutical company, is advancing in its mission to enhance patient outcomes with a focus on the central nervous system and immune system treatments. The company has successfully raised US$2.5 million to fund its strategic restructuring and has begun early sales of its innovative drugs like CannEpil® for Refractory Epilepsy and Cimetra® for ARDS, under special access schemes in UK, Ireland, and the USA. With fully autonomous EU-GMP manufacturing and R&D facilities in Malta and Slovenia, Argent is poised to address significant unmet medical needs and drive growth through a robust pipeline of potentially transformative medicines.
For further insights into AU:RGT stock, check out TipRanks’ Stock Analysis page.
